Advances in the Diagnosis and Treatment of Urothelial Cancers

Dear Colleagues,

Urothelial cancer disease has an increasing impact on populations, and their treatment is continuously evolving. A characteristic feature of management in this field is the significant heterogeneity among patients, which results in varied prognoses across clinical scenarios. Consequently, predicting responses to modern therapies and identifying novel combination treatments in cases of therapeutic failure remain major unmet needs in contemporary urologic oncology. Moreover, emerging diagnostic methods pose new challenges to current clinical guidelines and necessitate rigorous validation. Further progress is also needed in developing effective neoadjuvant and adjuvant treatment strategies for perioperative settings. Recent advances in systemic therapies, particularly immunotherapy, have provided new insights into adjuvant treatment approaches that may soon extend to localized disease. Finally, the ongoing progress in minimally invasive surgical techniques continues to reshape treatment concepts for many urothelial tumors.

This Special Issue aims to cover novel approaches in urothelial cancers, including blader cancer, upper tract urothelial carcinoma and urethral cancer. We welcome original papers and reviews relating to the advances in the diagnosis and treatment of all stages of urothelial cancers.

Dr. Aleksander Ślusarczyk
Dr. Łukasz Zapała
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.